Post-progression survival after treatment with epidermal growth factor receptor-tyrosine kinase inhibitor for advanced non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.
Yoshihito Kogure
No relevant relationships to disclose
Chiyoe Kitagawa
No relevant relationships to disclose
Masahide Oki
No relevant relationships to disclose
Hideo Saka
Consultant or Advisory Role - Lilly (U)
Honoraria - AstraZeneca; Chugai Pharma; Lilly; Taiho Pharmaceutical